These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20682371)

  • 1. Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.
    Saad F; Eastham JA
    Semin Oncol; 2010 Jun; 37 Suppl 1():S38-44. PubMed ID: 20682371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
    Lipton A; Colombo-Berra A; Bukowski RM; Rosen L; Zheng M; Urbanowitz G
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6397S-403S. PubMed ID: 15448038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
    Lipton A; Zheng M; Seaman J
    Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
    Saad F; Lipton A
    BJU Int; 2005 Nov; 96(7):964-9. PubMed ID: 16225510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
    Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
    Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
    Miwa S; Mizokami A; Konaka H; Izumi K; Nohara T; Namiki M
    Jpn J Clin Oncol; 2009 Nov; 39(11):745-50. PubMed ID: 19808839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.
    Kijima T; Fujii Y; Suyama T; Okubo Y; Yamamoto S; Masuda H; Yonese J; Fukui I
    BJU Int; 2009 Mar; 103(5):620-4. PubMed ID: 18990143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.
    Saad F; Eastham J
    Urology; 2010 Nov; 76(5):1175-81. PubMed ID: 21056263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
    Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
    J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates in lung cancer: more than a palliative therapy?
    Jahanzeb M; Hirsh V
    Semin Oncol; 2010 Jun; 37 Suppl 1():S45-52. PubMed ID: 20682372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.
    Henk HJ; Kaura S; Teitelbaum A
    J Med Econ; 2012; 15(1):195-204. PubMed ID: 22175657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid: multiplicity of use across the cancer continuum.
    Lipton A
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
    Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.
    Botteman MF; Meijboom M; Foley I; Stephens JM; Chen YM; Kaura S
    Eur J Health Econ; 2011 Dec; 12(6):575-88. PubMed ID: 20809091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors.
    Tchekmedyian NS; Chen YM; Saad F
    Cancer Invest; 2010 Oct; 28(8):849-55. PubMed ID: 20590447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.